Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating
Perspective Therapeutics Begins Shipping Investigational Products From State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey
Oppenheimer Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $22
Truist Financial Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $21
Perspective Therapeutics, Inc (CATX): A Small-Cap Pioneer in Targeted Cancer Therapies
A Quick Look at Today's Ratings for Perspective Therapeutics(CATX.US), With a Forecast Between $21 to $22